Since the expression of DSCAM-AS1 was dramatically elevated in many breast cancer and lung adenocarcinoma patients, we then investigated the clinical relevance of the altered expressions of DSCAM-AS1. This evidence concerns the gene PTGDR and breast carcinoma.